Literature DB >> 10972667

Chronic metabolic acidosis in azotemic rats on a high-phosphate diet halts the progression of renal disease.

A Jara1, A J Felsenfeld, J Bover, C R Kleeman.   

Abstract

BACKGROUND: Hyperphosphatemia and metabolic acidosis are general features of advanced chronic renal failure (RF), and each may affect mineral metabolism. The goal of the present study was to evaluate the effect of chronic metabolic acidosis on the development of hyperparathyroidism and bone disease in normal and azotemic rats on a high-phosphate diet. Our assumption that the two groups of azotemic rats (acid-loaded vs. non-acid-loaded) would have the same degree of renal failure at the end of the study proved to be incorrect.
METHODS: Four groups of rats receiving a high-phosphate (1.2%), normal-calcium (0.6%) diet for 30 days were studied: (1) normal (N); (2) normal + acid (N + Ac) in which 1.5% ammonium chloride (NH4Cl) was added to the drinking water to induce acidosis; (3) RF, 5/6 nephrectomized rats; and (4) RF + acid (RF + Ac) in which 0.75% NH4Cl was added to the drinking water of 5/6 nephrectomized rats to induce acidosis.
RESULTS: At sacrifice, the arterial pH and serum bicarbonate were lowest in the RF + Ac group and were intermediate in the N + Ac group. Serum creatinine (0.76 +/- 0.08 vs. 1.15 +/- 0.08 mg/dL), blood urea nitrogen (52 +/- 8 vs. 86 +/- 13 mg/dL), parathyroid hormone (PTH; 180 +/- 50 vs. 484 +/- 51 pg/mL), and serum phosphate (7.46 +/- 0.60 vs. 12.87 +/- 1.4 mg/dL) values were less (P < 0.05), and serum calcium (9.00 +/- 0.28 vs. 7.75 +/- 0.28 mg/dL) values were greater (P < 0.05) in the RF + Ac group than in the RF group. The fractional excretion of phosphate (FEP) was greater (P < 0.05) in the two azotemic groups than in the two nonazotemic groups. In the azotemic groups, the FEP was similar even though PTH and serum phosphate values were less in the RF + Ac than in the RF group. NH4Cl-induced acidosis produced hypercalciuria in the N + Ac and RF + Ac groups. When acid-loaded (N + Ac and RF + Ac) and non-acid-loaded (N and RF) rats were combined as separate groups, serum phosphate and PTH values were less for a similarly elevated serum creatinine value in acid-loaded than in non-acid-loaded rats. Finally, the osteoblast surface was less in the N + Ac group than in the other groups. However, in the acid-loaded azotemic group (RF + Ac), the osteoblast surface was not reduced.
CONCLUSIONS: The presence of chronic metabolic acidosis in 5/6 nephrectomized rats on a high-phosphate diet (1) protected against the progression of RF, (2) enhanced the renal clearance of phosphate, (3) resulted in a lesser degree of hyperparathyroidism, and (4) did not reduce the osteoblast surface. The combination of metabolic acidosis and phosphate loading may protect against the progression of RF and possibly bone disease because the harmful effects of acidosis and phosphate loading may be counterbalanced.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972667     DOI: 10.1046/j.1523-1755.2000.00260.x

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  15 in total

1.  Improved pulmonary vascular reactivity and decreased hypertrophic remodeling during nonhypercapnic acidosis in experimental pulmonary hypertension.

Authors:  Helen Christou; Ossama M Reslan; Virak Mam; Alain F Tanbe; Sally H Vitali; Marlin Touma; Elena Arons; S Alex Mitsialis; Stella Kourembanas; Raouf A Khalil
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2012-01-27       Impact factor: 5.464

2.  NH4Cl Treatment Prevents Tissue Calcification in Klotho Deficiency.

Authors:  Christina B Leibrock; Ioana Alesutan; Jakob Voelkl; Tatsiana Pakladok; Diana Michael; Erwin Schleicher; Zahra Kamyabi-Moghaddam; Leticia Quintanilla-Martinez; Makoto Kuro-o; Florian Lang
Journal:  J Am Soc Nephrol       Date:  2015-02-02       Impact factor: 10.121

Review 3.  Short- and long-term effects of alkali therapy in chronic kidney disease: a systematic review.

Authors:  Paweena Susantitaphong; Kamal Sewaralthahab; Ethan M Balk; Bertrand L Jaber; Nicolaos E Madias
Journal:  Am J Nephrol       Date:  2012-05-29       Impact factor: 3.754

4.  High Dietary Acid Load Predicts ESRD among Adults with CKD.

Authors:  Tanushree Banerjee; Deidra C Crews; Donald E Wesson; Anca M Tilea; Rajiv Saran; Nilka Ríos-Burrows; Desmond E Williams; Neil R Powe
Journal:  J Am Soc Nephrol       Date:  2015-02-12       Impact factor: 10.121

5.  Bicarbonate supplementation slows progression of CKD and improves nutritional status.

Authors:  Ione de Brito-Ashurst; Mira Varagunam; Martin J Raftery; Muhammad M Yaqoob
Journal:  J Am Soc Nephrol       Date:  2009-07-16       Impact factor: 10.121

Review 6.  Consequences and therapy of the metabolic acidosis of chronic kidney disease.

Authors:  Jeffrey A Kraut; Nicolaos E Madias
Journal:  Pediatr Nephrol       Date:  2010-06-05       Impact factor: 3.714

Review 7.  Acidosis: progression of chronic kidney disease and quality of life.

Authors:  Ione de-Brito Ashurst; Emma O'Lone; Tarun Kaushik; Kieran McCafferty; Muhammad M Yaqoob
Journal:  Pediatr Nephrol       Date:  2014-08-02       Impact factor: 3.714

8.  Acetazolamide sensitive tissue calcification and aging of klotho-hypomorphic mice.

Authors:  Christina B Leibrock; Ioana Alesutan; Jakob Voelkl; Diana Michael; Tatsiana Castor; Ursula Kohlhofer; Leticia Quintanilla-Martinez; Laura Kübler; Julia G Mannheim; Bernd J Pichler; Kevin P Rosenblatt; Makoto Kuro-o; Florian Lang
Journal:  J Mol Med (Berl)       Date:  2015-08-27       Impact factor: 4.599

9.  Vascular calcification and metabolic acidosis in end stage renal disease.

Authors:  D Yonova
Journal:  Hippokratia       Date:  2009-07       Impact factor: 0.471

10.  Effect of oral sodium bicarbonate supplementation on progression of chronic kidney disease in patients with chronic metabolic acidosis: study protocol for a randomized controlled trial (SoBic-Study).

Authors:  Martina Gaggl; Daniel Cejka; Max Plischke; Georg Heinze; Melanie Fraunschiel; Alice Schmidt; Walter H Hörl; Gere Sunder-Plassmann
Journal:  Trials       Date:  2013-07-04       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.